share_log

Needham Reiterates Buy on Rocket Pharmaceuticals, Maintains $53 Price Target

Moomoo 24/7 ·  Apr 10 06:08

Needham analyst Gil Blum reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $53 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment